0000950170-24-004264.txt : 20240112 0000950170-24-004264.hdr.sgml : 20240112 20240112163156 ACCESSION NUMBER: 0000950170-24-004264 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240103 FILED AS OF DATE: 20240112 DATE AS OF CHANGE: 20240112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ciulla Thomas CENTRAL INDEX KEY: 0001815426 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36483 FILM NUMBER: 24532445 MAIL ADDRESS: STREET 1: C/O CLEARSIDE BIOMEDICAL, INC. STREET 2: 900 NORTH POINT PARKWAY, SUITE 200 CITY: ALPHARETTA STATE: GA ZIP: 30005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viridian Therapeutics, Inc.\DE CENTRAL INDEX KEY: 0001590750 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 471187261 STATE OF INCORPORATION: DE FISCAL YEAR END: 1215 BUSINESS ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BLDG. 17, SUITE 401 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 617.272.4600 MAIL ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BLDG. 17, SUITE 401 CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC. DATE OF NAME CHANGE: 20170213 FORMER COMPANY: FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC. DATE OF NAME CHANGE: 20170213 FORMER COMPANY: FORMER CONFORMED NAME: SIGNAL GENETICS, INC. DATE OF NAME CHANGE: 20140710 3 1 ownership.xml 3 X0206 3 2024-01-03 0 0001590750 Viridian Therapeutics, Inc.\DE VRDN 0001815426 Ciulla Thomas C/O VIRIDIAN THERAPEUTICS, INC. 221 CRESCENT STREET, SUITE 401 WALTHAM MA 02453 false true false false Chief Medical Officer Common Stock 762 D Stock Option (Right to Buy) 33.06 2033-03-01 Common Stock 250000 D Stock Option (Right to Buy) 28.22 2033-04-25 Common Stock 50000 D Stock Option (Right to Buy) 13.76 2033-11-10 Common Stock 270000 D This option represents a right to purchase a total of 250,000 shares of the Issuer's common stock, 25% of which will vest on February 17, 2024, with the remaining vesting in approximately equal monthly installments through February 17, 2027, subject to the Reporting Person's continued service to the Issuer. This option represents a right to purchase a total of 50,000 shares of the Issuer's common stock, 8,333 of which have vested, with the remaining vesting in approximately equal monthly installments through April 25, 2027, subject to the Reporting Person's continued service to the Issuer. This option represents a right to purchase a total of 270,000 shares of the Issuer's common stock, 11,250 of which have vested, with the remaining vesting in approximately equal monthly installments through November 10, 2027, subject to the Reporting Person's continued service to the Issuer. /s/ Thomas Ciulla 2024-01-12